Logo.jpg
ProPhase Labs Announces Formation of ProPhase BioPharma, Inc. (PBIO) for the Licensing and Development of Novel Drugs, Compounds and Biotechnology
June 28, 2022 08:30 ET | ProPhase Labs, Inc.
Company Also Announces First Licensing Agreement for PBIO with Global BioLife, Inc. for broad based Anti-Viral Fighting Compounds Equivir and Equivir G Garden City, NY, June 28, 2022 (GLOBE...
logo.jpg
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
May 12, 2022 08:30 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
logo.jpg
Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
August 11, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
Live video webcast with David Baker, President and CEO of Vallon, on Wednesday, August 18th 12:30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:...
logo.jpg
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
April 26, 2021 09:05 ET | Vallon Pharmaceuticals Inc.
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon...
logo.jpg
Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
March 03, 2021 08:35 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
logo.jpg
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2021 15:30 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
logo.jpg
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 09, 2021 22:24 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that...
MNTA Logo.jpg
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 39th Annual Global Healthcare Conference
June 06, 2018 16:02 ET | Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will present at the Goldman Sachs 39th Annual Global Healthcare Conference. ...
MNTA Logo.jpg
Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity
May 17, 2018 16:05 ET | Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the upcoming presentation describing the broad potential for anti-FcRn therapeutics and...
MNTA Logo.jpg
Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch Health Care Conference 2018
May 10, 2018 08:00 ET | Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...